HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9120 | Dactinomycin | Cosmegen | 0.5 mg | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | No | 1964 | Jan 1, 1984 | In Use | ||
J9208 | Ifosfamide | Ifosfamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1988 | Jan 1, 1999 | In Use | ||
J9100 | Cytarabine | Cytarabine | 100 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 1986 | In Use | ||
J9171 | Docetaxel | Taxotere | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1996 | Jan 1, 2010 | In Use | ||
NA | Estramustine Phosphate Sodium | Emcyt | 140 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1981 | In Use | |||
J9230 | Mechlorethamine | Mustargen | 10 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1949 | Jan 1, 1986 | In Use | ||
J9046 | Bortezomib (Dr Reddy) | Bortezomib (Dr Reddy) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2022 | Dec 21, 2022 | In Use | ||
J9182 | Etoposide | Toposar, Etopophos | 100 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | No | 1983 | Jan 1, 1987 | Dec 31, 2008 | No Longer Used | |
C9205 | Oxaliplatin | Eloxatin | unspecified | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2002 | Jul 1, 2003 | Dec 31, 2005 | No Longer Used | |
J9056 | Bendamustine hydrochloride (Vivimusta) | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
NA | Dasatinib | Sprycel | 140 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
NA | Gilteritinib | Xospata | 40mg | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Yes | 2018 | In Use | |||
Vorasidenib | Voranigo | 10mg,40mg | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Yes | 2024 | In Use | ||||
J9033 | Bendamustine Hcl | Bendamustine Hcl | 1 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2008 | Jan 1, 2009 | In Use | ||
NA | Pralsetinib | Gavreto | 100mg | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Yes | 2020 | In Use | |||
J9351 | Topotecan | Hycamtin | 0.1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2011 | In Use | ||
J9223 | Lurbinectedin | Zepzelca | 0.1mg | Chemotherapy | Alkylating Agent | Adduct Forming Agent | No | 2020 | Jan 1, 2021 | In Use | ||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
J9357 | Valrubicin | Valstar | 200 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1998 | Jan 1, 2000 | In Use | ||
NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec 7, 2023 | In Use | ||
NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
J9110 | Cytarabine | Cytarabine | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.